Elevation Oncology Inc ELEV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/02/24 EDT
3.80quote price arrow down-0.02 (-0.52%)
Volume
4,307
Close
3.82UNCH (UNCH)
Volume
1,931,472
52 week range
0.36 - 5.89
Loading...
  • Open3.73
  • Day High4.14
  • Day Low3.18
  • Prev Close3.82
  • 52 Week High5.89
  • 52 Week High Date05/26/23
  • 52 Week Low0.36
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap208.718M
  • Shares Out54.64M
  • 10 Day Average Volume1.02M
  • Dividend-
  • Dividend Yield-
  • Beta1.37
  • YTD % Change611.36

KEY STATS

  • Open3.73
  • Day High4.14
  • Day Low3.18
  • Prev Close3.82
  • 52 Week High5.89
  • 52 Week High Date05/26/23
  • 52 Week Low0.36
  • 52 Week Low Date11/13/23
  • Market Cap208.718M
  • Shares Out54.64M
  • 10 Day Average Volume1.02M
  • Dividend-
  • Dividend Yield-
  • Beta1.37
  • YTD % Change611.36

RATIOS/PROFITABILITY

  • EPS (TTM)-1.53
  • P/E (TTM)-2.50
  • Fwd P/E (NTM)-4.52
  • EBITDA (TTM)-40.299M
  • ROE (TTM)-88.03%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)54.99%

EVENTS

  • Earnings Date05/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Elevation Oncology Inc

 

Profile

MORE
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1...
Steven Elms
Chairman of the Board
Joseph Ferra Jr.
President, Chief Executive Officer, Director
Tammy Furlong CPA
Chief Financial Officer
Address
101 Federal Street, Suite 1900
Boston, MA
02110
United States

Top Peers

SYMBOLLASTCHG%CHG
ANVS
Annovis Bio Inc
5.45UNCHUNCH
CMPX
Compass Therapeutics Inc.
1.65UNCHUNCH
XFOR
X4 Pharmaceuticals Inc
1.08UNCHUNCH
LENZ
LENZ Therapeutics Inc
16.41UNCHUNCH
ATOS
Atossa Therapeutics Inc
1.52UNCHUNCH